About Xenon Pharmaceuticals
A neuroscience-focused biopharmaceutical company
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Burnaby, BC
- Company type
- Public Company
- Company profile name
- Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. We have offices in Vancouver, British Columbia, and Boston, Massachusetts.
Specialties
- biotechnology
- ion channel science
- neurology
- epilepsy
- depression
- and pain
Company locations
3650 Gilmore Way, Burnaby, BC V5G 4W8, CA
117 Kendrick Street, Suite 200, Needham, MA 02494, US
Locations on the company profile may be outside this area. Not every location is hiring.
Business areas
- Biopharma
- Biotechnology
- Genetics
- Health Care
- Medical
- Pharmaceutical
- Biotech & Pharmaceuticals
- Pharmaceutical and biotechnology
On LinkedIn
- Followers
- 28,085
- People linked to this company
- 421
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
1,838,329,717 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.